Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive with systemic therapy alone. Definitive treatment of the metastatic deposit remains the sole potentially curative option and is a cornerstone of mRCC therapy, offering potential for both local control and palliation of tumor-related symptoms. In this review, the evidence supporting the definitive treatment of mRCC is examined and summarized, including the use of surgical metastasectomy, thermal ablation, radiotherapy, and other minimally invasive options. Multimodal approaches, including the combination of metastasectomy with novel systemic agents, are discussed. Finally, the authors review considerations for patient selection for this type of therapy and summarize available risk-stratification tools that may help guide shared decision making. Cancer
HISTORIC PERSPECTIVE AND THE RATIONALE FOR METASTASECTOMY
The incidence of renal cell carcinoma (RCC) is increasing worldwide, with nearly 64,000 new diagnoses expected in the United States in 2017. 1 The highest annual percent change in incidence has occurred in young patients. 2 Although the ubiquity of cross-sectional imaging has resulted in stage migration such that small, incidentally detected renal masses constitute an increasing proportion of these tumors, from 20% to 40% of contemporary patients with a new diagnosis of RCC present with metastatic disease. [3] [4] [5] Among those with localized disease, an additional 25% will develop metastases after definitive local therapy. [6] [7] [8] RCC metastases are often multifocal, commonly involving the lungs (45%), bones, lymph nodes, liver, brain, and (more rarely) the other viscera and endocrine organs. 9 Metastatic RCC (mRCC) is considered a lethal disease with a historic median survival of 12 months. 10 However, contemporary population-based analyses from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database demonstrate substantial improvements in cancer-specific mortality (CSM) among patients who have mRCC, with the 24-month CSM declining from 67.3% during 2001 through 2005, to 63.7% during 2006 through 2009, and to 61% during 2010 through 2014. 11 Unfortunately, complete responses with contemporary targeted agents are rare and do not approach those observed in 3% to 8% of patients who receive high-dose interleukin-2, albeit with significant associated toxicity. 12 The recently approved checkpoint inhibitor nivolumab has demonstrated objective responses rates of 20% to 22%, with durable responses beyond 24 months noted in approximately 8% of patients reported to date. 13 Longer term follow-up for this and other novel immunotherapy agents is eagerly anticipated. Historically, before the advent of systemic mRCC therapy, surgical extirpation of the primary disease and metastatic sites was anecdotally reported to result in a durable disease-free survival in carefully selected patients. Barney and Churchill are credited with the first report (in 1939) of cytoreductive nephrectomy with pulmonary metastasectomy in a patient with mRCC, in which the patient subsequently survived an additional 23 years before dying from coronary artery disease. 14 Subsequent observational studies have demonstrated that carefully selected patients with mRCC may be rendered disease-free after resection or ablation of the primary tumor and metastatic sites, leading to the contention that metastasectomy offers the best opportunity to achieve a durable disease-free period. 5, 15 However, it is unclear whether the results reported in those retrospective studies are secondary to favorable tumor biology, patient selection, the role of metastasectomy itself, or the interaction of these factors. Other benefits of directly treating the metastases include palliation of tumor-related symptoms as well as permitting periods without systemic therapy, thus avoiding or deferring treatmentassociated toxicity.
In this review, we examine the evidence available regarding the definitive treatment of metastatic deposits in patients with metastatic kidney cancer and review its role in the context of multimodal therapy, including novel systemic agents. Specifically, we address the different modalities that may be used to remove, ablate, or otherwise render the patient without evidence of disease, with emphasis on both surgical and nonsurgical treatment options, the latter of which are being used with increasing frequency. Finally, we discuss considerations of patient selection for this type of therapy and summarize patientselection tools that may inform shared decision making and the development of personalized treatment plans for patients with mRCC.
ONCOLOGIC OUTCOMES

Complete Versus Incomplete Metastasectomy/ Absence of Metastasectomy
Although there are no available randomized controlled trials to support the use of locally directed therapy against RCC metastases as of the writing of this report, a body of observational data elaborates the potential for metastasectomy to effect palliation of symptoms as well as durable periods of disease-free survival and, in rare cases, a cure.
Providing the highest level of evidence available, 2 recent systematic reviews have aimed to quantify the benefit to integrating definitive local treatment of metastases in the management of mRCC. 16, 17 In 2014, Dabestani and colleagues examined the evidence supporting the definitive local treatment of metastases in mRCC. 16 Among 6 of 8 studies that compared outcomes between patients who underwent complete metastasectomy (CM) with those who underwent incomplete or no metastasectomy, CM was associated with a significantly longer overall survival (OS) and cancer-specific survival (CSS) (median of medians [OS or CSS], 40.8 vs 14.8 months). Of the 2 remaining studies, 1 demonstrated nonstatistically different CSS when comparing metastasectomy versus no metastasectomy (58 vs 50 months; P 5 .2), although the cohort size was relatively small (n 5 18 vs 16). 18 The other study reported longer survival associated with CM without statistical comparison (30 vs 12 months). 19 A forest plot summary of the hazard ratios (HRs) between CM and CSS and OS across organ sites unequivocally favored CM.
Zaid and colleagues presented a recent systemic review specifically assessing complete surgical metastasectomy in mRCC. 17 In total, 8 retrospective cohort studies were included, in which 958 patients who underwent CM were compared with 1309 who underwent either partial or no metastasectomy. CM was associated with a median OS ranging from 36.5 to 142 months versus 8.4 to 27 months among those who underwent incomplete/no metastasectomy (pooled adjusted HR, 2.37; 95% confidence interval [CI], 2.03-2.87; P < .001) with low heterogeneity.
Local Treatment Without Concurrent Systemic Treatment
Commonly, mRCC is managed using a multidisciplinary approach that incorporates systemic and locally directed therapy. However, in patients who have oligometastatic or low-volume metastatic disease, metastasectomy may permit delaying the initiation of systemic therapy or may provide the opportunity to withdraw therapy for a period, thereby sparing the patient the associated toxicities (eg, see Fig. 1 ) Kavolius and colleagues analyzed 278 patients diagnosed between 1980 and 1993 who had recurrent mRCC after undergoing primary nephrectomy, of whom 141 underwent CM alone and attained 5-year CSS and OS rates of 36% and 44%, respectively. 20 Conversely, the 5-year CSS and OS rates for patients who received systemic therapy or underwent incomplete metastasectomy were 11% and 14%, respectively. Among those who recurred after CM, 110 patients underwent subsequent repeat resection, including 62 who were rendered disease-free with a 5-year OS of 46%. Among these patients, an additional 22 underwent curative resection of a third recurrence, with a 5-year OS of 44%.
With demonstration of the feasibility of metastasectomy for oligometastatic mRCC, CM was subsequently attempted in patients who had multiple synchronous metastases. Alt et al reported on 887 patients who underwent multiple metastectomy after nephrectomy, 21 of whom 792 underwent 3 procedures and 483 underwent with surgery alone, including 125 who underwent CM. Among those who underwent curative resection, 28% also received systemic therapy. The median CSS for those who did and did not receive systemic therapy in addition to CM were comparable (4.5 vs 5.7 years; P 5 .98). introduced in the past decade (for review, see Appleman and Maranchie 22 ). Most recently, the potential benefit of immune checkpoint inhibitors in mRCC has garnered recognition. In 2015 nivolumab, an antiprogrammed cell death protein-1 antibody, demonstrated improved OS compared with everolimus and thus was approved as a second-line agent for mRCC. 23 Because the landscape for systemic therapy for mRCC is rapidly evolving, most observational studies include heterogeneous systemic approaches, thereby making it a challenge to draw conclusions about the specific effects of definitive local therapy with each individual systemic agent.
In the cytokine era, among 1463 Japanese patients who were diagnosed with mRCC between 1988 and 2002 (of whom 82.4% received cytokine-based therapy and 20.8% underwent metastasectomy), metastasectomy was associated with improvements in median OS (44.3 6 5 months vs 16.4 6 1.8 months; P < .0001) 24 . Similarly, Daliani et al described 38 patients who received 4 months of immunotherapy with or without chemotherapy and underwent metastasectomy with curative intent, followed by consolidative adjuvant therapy in 89%. 25 In total, 29 of those patients (76%) were rendered diseasefree after metastasectomy. The median progression-free survival (PFS) was 1.8 years, and 8 (21%) patients remained disease free.
In the era of targeted therapy, Yu and colleagues 26 reported on 96 patients with mRCC, of whom 31 underwent CM, 11 underwent partial metastasectomy, and 54 received targeted agents. Among the patients who underwent surgery, systemic therapy was received only by those who had progressive or inoperable disease. The median OS was 52 versus 16 versus 22 months for CM, targetedtherapy only, and incomplete resection, respectively (P 5 .001).
Regarding treatment sequencing, some authors have proposed administering neoadjuvant, targeted therapy before metastasectomy. In a series of 22 patients who underwent CM after receiving at least 1 cycle of targeted therapy and had a median follow-up of 109 weeks, there was a single death from RCC, and 50% of patients had attained a durable complete response at a median of 43 weeks. 27 Further systemic therapy was required in 9 patients, whereas the remaining 13 patients did not receive any additional treatment. In another series of 143 patients with mRCC who received immunotherapy (n 5 59), tyrosine kinase inhibitors (n 5 49), or immunotherapy followed by tyrosine kinase inhibitors (n 5 35), of whom 43 also underwent CM, metastasectomy was associated with a nonstatistically significant increase in OS (median, 18.8 vs 15 months; P 5 .07). 28 The receipt of adjuvant systemic therapy after CM is an area of particular interest for which current data are limited. Patients with mRCC who are rendered disease free after locally directed therapy represent a unique clinical cohort. 22 Although their tumors demonstrate the ability and propensity to metastasize, in the absence of observable disease, the role of further systemic therapy and the balance between uncertain oncologic benefit and risk treatment-associated toxicity are poorly understood. Hence deferring systemic therapy can be considered during shared decision making.
Kwak and colleagues evaluated 93 patients who underwent metastasectomy, of whom 20 received no further treatment, whereas 73 received adjuvant immunotherapy. 29 The 1-year, 3-year, and 5-year survival rates for the surgery-only versus adjuvant immunotherapy groups were 65.4% and 65.9%, 38.5% and 22.7%, and 11.5% and 2.3%, respectively (P 5 1.0). After multivariable analysis adjusting for confounding factors, including the time to metastasis, performance status, metastatic site, and prior nephrectomy, there remained no statistically significant association between adjuvant immunotherapy and OS.
Currently, several ongoing clinical trials are endeavoring to further quantify the benefit of adjuvant systemic therapy after metastasectomy. RESORT is a randomized, open-label multicenter phase 2 study that will assess the efficacy of adjuvant sorafenib after metastasectomy in 132 patients with a goal of 36 months of follow-up. 30 SMAT-AN (Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma With or Without Adjuvant Sunitinib Therapy 20/04 (clinicaltrials.gov identifier NCT01216371) is a German phase 2 study that will randomize patients with clear cell mRCC who have undergone pulmonary metastasectomy to receive 1 year of adjuvant sunitinib versus expectant management with a primary endpoint of 2-year PFS. 31 An Eastern Cooperative Oncology Group-American College of Radiology Imaging Network study (ECOG 2810) is currently enrolling patients with completely resected mRCC (clear cell) to receive 1 year of pazopanib versus placebo to assess the primary endpoint of disease-free survival (clinicaltrials.gov identifier NCT01575548). Patients with brain metastases will be excluded. Randomization will be stratified by the number of sites of resected metastatic disease and by the disease-free interval. There are also 2 ongoing trials addressing the role of checkpoint inhibitors in this arena. A nonrandomized study of the programmed
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Cancer September 15, 2018 dealth-1 antibody pembrolizumab in combination with stereotactic radiosurgery is recruiting patients with oligometastatic mRCC (clinicaltrials.gov identifier NCT02855203). Finally, a placebo-controlled, randomized study of adjuvant atezolizumab (a programmed dealth-1 ligand antibody) after either radical nephrectomy or CM is underway.
On the basis of the available data, pending the results from these ongoing clinical trials, some authors believe that the standard of care after CM is observation for patients who have no evidence of disease. 22 However, given the absence of level 1 data, the receipt of adjuvant therapy after CM should be decided on a case-by-case basis at this time.
APPROACHES TO THE LOCAL TREATMENT OF RCC METASTASES
Surgical Considerations and Complications Related to Metastasectomy
The surgical approach to RCC metastases requires a multidisciplinary team. In addition to the urologist, depending on the location, a surgical team comprised of members with expertise in cardiothoracic, hepatobiliary, colorectal, and endocrine surgery; surgical oncology; orthopedics; and neurosurgery may need to be involved in addition to an experienced anesthesia team. Perioperative management may necessitate the involvement of intensivists, depending on the extent of surgery and the stability of the patient. Furthermore, the complexity of the surgical excision of metastases depends variously on the size of the metastatic deposit, its local extent, and the potential need to resect neighboring organs to obtain a negative margin, as well as on the surgical environment, such as the proximity to a field that has previously been explored, ablated, or irradiated. 32 Technical feasibility also is contingent upon a patient's burden of comorbidity and functional status, which may determine the safety of submitting the patient to general anesthesia and a potentially complex operation.
With respect to perioperative outcomes after metastasectomy, the available literature addressing both complications and quality-of-life issues after surgical resection of mRCC deposits is sparse. Among 22 patients who underwent CM after receiving neoadjuvant targeted therapy, metastasectomy was associated with a total of 6 postoperative complications in 4 patients within 12 months of surgery. 27 Surgical resection of osseous mRCC is associated with a high risk of substantial intraoperative blood loss, with a risk of major postoperative complications in nearly 25% of patients; therefore, preoperative angioembolization approaches are frequently used. 33 Joyce et al observed a higher risk of thromboembolic complications among patients who underwent nephrectomy and simultaneous hepatic resection for locally advanced RCC involving the liver or hepatic metastases compared with a referent cohort that underwent nephrectomy and resection of nonhepatic metastases or locally advanced disease, without differences in overall moderate-to-severe complications or perioperative mortality. 34 Recently, Meyer and colleagues performed a population-based analysis in which they described inhospital complication rates after surgical metastasectomy in a contemporary mRCC cohort. 35 Among 45,279 patients with mRCC, 1102 (2.4%) underwent surgical metastasectomy between 2000 and 2011, predominantly comprised of metastases from the lung (43.5%), bone (27.1%), and liver (16.1%). Intraoperative complications were observed in 7.9% of patients. The overall complication rate was 45.7%, whereas major complications (Clavien classification, III-IV) occurred in 25.1% of patients, and the in-hospital mortality rate was 2.4%. On univariable analysis, an increased risk of major complications was associated with a higher comorbidity score, resection after 2006, and private insurance; whereas race, sex, hospital volume or location, and metastatic location were not significantly associated. These results are consistent with prior single-institution reports that described major complications in approximately 25% of patients who underwent metastasectomy 27, 36 and in-hospital mortality in 0.9% to 2.3%. 37, 38 In terms of determining the optimal timing of metastasectomy with respect to cytoreductive nephrectomy in patients with synchronous metastases, high-volume centers have described the safety and feasibility of concurrent metastasectomy in carefully selected patients. 34, 39 However, to our knowledge, there are limited data regarding the comparative efficacy of metastasectomy at the time of cytoreductive nephrectomy versus delayed treatment of metastases. Recommendations regarding combined versus separate procedures must be approached on a case-by-case basis, taking into account the complexity of a combined surgical procedure, the location of the metastases with respect to the kidney (eg, osseous or pulmonary metastases may require separate incisions and different surgical equipment), the availability of other modalities to treat the metastatic deposits (eg, thermal ablation and radiotherapy; see sections below), and the fitness of the patient to undergo a potentially longer, more complex procedure. However, for patients who have intraabdominal metastases amenable to resection at the time of cytoreductive nephrectomy, synchronous removal at the incident procedure precludes the risks associated with a secondary abdominal surgery and should be considered.
Percutaneous Thermal Ablation
Achieving local control of mRCC may also be achieved by nonsurgical methods. Percutaneous ablation of primary small RCC was first described in 1999. 40 Percutaneous thermal ablation of clinical T1A (cT1a) and select cT1b renal masses by cryoablation and radiofrequency ablation has demonstrated efficacy in terms of local disease control compared with nephron-sparing surgery along with low rates of complications. [41] [42] [43] This technology has subsequently been extended to the treatment of RCC local recurrences and metastases. Welch et al described the use of percutaneous image-guided ablation of 82 mRCC lesions in 61 patients, including metastases to the liver, adrenal gland, spine/paraspinal region, bones, nephrectomy bed/retroperitoneum, body wall, muscles, lung, and diaphragm. 44 In total, the authors reported 4 (4.9%) technical failures in which primary control of the metastasis was not achieved. Among the 76 patients who had > 3 months of follow-up, the authors identified 6 local recurrences 7 to 33 months after mRCC ablation. The estimated 3-year OS rate was 76%. There were 3 moderateto-severe complications, all of which occurred after the ablation of adrenal metastases, and there was no periprocedural mortality.
Bang and colleagues demonstrated similar efficacy when treating 27 patients who had a total of 72 mRCC tumors using either computed-tomography-guided or ultrasound-guided cryoablation. 45 Major complications occurred in 2% of patients, local recurrences were documented in 3%, and the median OS was 2.7 years. Those authors performed a cost analysis in which they estimated a total cost of $54,833, including both treatment and posttreatment imaging surveillance. By comparison, best supportive care was estimated to cost $28,312 compared with $31,347 for interferon-a monotherapy, $59,554 for bevacizumab with interferon, $43,366 for sorafenib, and $50,707 for sunitinib. Cryoablation as an adjunct to standard, systemic, targeted therapies for mRCC was determined to be cost effective versus historic cost comparisons, with an adjunctive cost-effectiveness ratio of $28,312 to $59,554 per life-year gained.
With the growing availability of percutaneous image-guided ablative technology and the development of expertise in treating both primary tumors and metastases in different viscera and regions within the body, both technical success and primary efficacy have been demonstrated in the use of magnetic resonance imaging-directed laser ablation, cryoablation, radiofrequency ablation, and microwave ablation of RCC metastases involving the adrenal gland, 46 ,47 the appendicular and axial skeleton, 48, 49 and the lungs. [50] [51] [52] Therefore, particularly in patients who have low-volume metastatic disease who may not be surgical candidates, percutaneous thermal ablation appears to be a reasonable approach to consider.
Radiation Therapy
Because of a generally held belief that RCC is a radioresistant tumor and concerns for potential radiotoxicity to the surrounding viscera, radiation therapy is not generally included in the management of primary RCC. However, mounting observational data have challenged this paradigm. De Meerleer et al reviewed the use of radiotherapy for RCC, delineating a biologic rationale for the radiosensitivity of RCC to stereotactic radiotherapy based on activation of the ceramide pathway, which is activated at high doses. 53 Those authors further proposed that radiation might induce an indirect abscopal immunologic effect that may be synergistic when combined with targeted agents.
Indeed, a recent systematic review evaluating 10 studies and 126 patients demonstrated that stereotactic radiosurgery (SRS) may even have utility in the management of primary RCC, with a 93% weighted local response rate and reports of moderate-to-severe complication in 3.8%. 54 Indeed, radiotherapy has demonstrated utility in the management of mRCC both as monotherapy and as adjuvant therapy to surgical resection [55] [56] [57] and in the management of osseous, [58] [59] [60] [61] pulmonary, 62 brain, 63 and pancreatic metastases. 64 Brachytherapy, which permits the delivery of high-dose radiation to a specific location, has demonstrated efficacy for amenable metastatic deposits, like those in a patient who had mRCC metastasis to the tongue. 65 A systematic review of SRS 66 evaluated a total of 810 patients with 2433 intracranial targets and an estimated 1-year weighted local control rate of 88% for intracranial mRCC with a 1-year OS rate of 36% to 90% and a 2-year OS rate of 15% to 54%. Factors associated with improved OS included younger age, higher performance status, and prior whole-brain radiation. Grade 3 and 4 toxicity was reported in 2% to 3% of patients, whereas treatment-related mortality occurred in 0.6%, all of which were secondary to intratumoral hemorrhage. In the extracranial literature, the authors identified 10 publications, including 389 patients with 730 targets. All but 2 publications in the extracranial literature used linear-acceleratorbased delivery systems, whereas 2 others used cyberknife
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Cancer September 15, 2018 technology. The weighted crude local control rate was estimated at 89% overall and 86% at 1 year, with a median OS of 12 ton 22 months. Improvement in local symptoms was reported by 5 studies in 69% of patients, and 1 study reported complete pain relief in 67% of patients at 9 months. Grade 3 and 4 toxicity reports ranged from 0% to 4%, with 2 incidents of treatmentrelated mortality.
A contemporary series of 175 metastatic extracranial lesions in 84 patients who underwent SRS reported a 1-year local control rate of 91.2% (95% CI, 84.9%-95%). 67 Local failures were associated with a history of radiation, palliative-intent radiation, spine location, and a lower biologically effective dose (<115 grays [Gy]). Acute and late grade 3 toxicity was reported in 1.7% and 2.9% of patients, respectively. In another series of 53 soft-tissue mRCC targets treated with either SRS (n 5 36) or conventional external-beam radiotherapy (EBRT), 68 the median biologically effective dose was 216.67 Gy for SRS and 60 Gy for EBRT. Local control rates at 12 and 24 months were 100% versus 62% and 93.4% versus 35.3% for SRS and EBRT, respectively; however, the limited sample size precluded multivariable analysis to identify features that were associated independently with local control. Consistently, the factor that most strongly associated with improved local control rates when using radiation therapy in mRCC is being able to deliver local doses of radiation. 66, 69 In the targeted therapy era, high-dose local radiation to mRCC targets has been combined with systemic agents and has demonstrated efficacy. A recent phase 1 dose-escalation study (clinicaltrials.gov identifier NCT02334709) combined SRS to the largest metastatic lesion in 13 patients who had mRCC with pazopanib, and the combination produced a 1-year local control rate of 83% and a 1-year PFS rate of 28%. 70 Finally, radiation may be used as an adjunct to surgical metastasectomy. Paly and colleagues reported on a multi-institutional cohort of 98 patients who received intraoperative radiation therapy at the time of RCC resection, including 71 who underwent resection of locally recurrent RCC. 71 The median intraoperative radiation therapy dose was 15 Gy. Thirty-two percent and 31% of patients received preoperative or postoperative EBRT, respectively. OS at 1 year and 5 years was 96% and 60%, respectively. There was a 29% perioperative complication rate in that series, and there were 2 perioperative deaths.
Currently, radiation therapy appears to have demonstrated benefit in the control of both intracranial and extracranial mRCC with respect to local control as well as metastasis-related symptom palliation. In terms of the association between the receipt of radiotherapy and patient-reported outcomes, results from the PERCEP-TION prospective patient registry trial demonstrated that exposure to radiotherapy was independently associated with inferior health-related quality-of-life outcomes, as demonstrated using the EuroQol Group 5D (EQ-5D) health outcome instrument. 72 However, the investigators hypothesized that this correlation may have been strongly driven by the finding that radiotherapy is commonly used in the mRCC space for palliation of local symptomatic disease, which reportedly also drives quality-of-life utilities. Prospective, randomized, controlled studies assessing durable control rates and the effect of combined systemic therapy and targeted radiation therapy are needed to better define patient selection and optimize radiation dosing strategies to maximize efficacy and minimize toxicity.
Embolization
Embolization is also incorporated into the local treatment of metastatic disease with the objective of achieving local control, decreasing blood loss during surgical metastasectomy, and palliating mRCC-related symptoms. The resection of spinal mRCC metastases, which are frequently hypervascular, is associated with the potential for substantial intraoperative blood loss and massive transfusion requirement. In a systematic review of 6 studies (n 5 105 patients and 101 controls) who received preoperative embolization before spinal metastasectomy, 73 embolization was performed 1 to 3 days before surgery. Intraoperative blood loss in those who received embolization ranged from 1785 to 6756 mL compared with 2895 to 4827 mL in controls. Conversely, forest plots did not demonstrate any difference in blood loss from the receipt preoperative embolization before spinal metastasectomy. However, these results appear to have been driven by a small series of 15 patients in which those who received embolization had markedly higher intraoperative blood loss. 74 On sensitivity analysis, when this study was excluded, the mean difference in intraoperative blood loss was 1227 mL less in the embolization group compared with the control group (pooled standard mean difference, 0.88; 95% CI, 0.39-1.36; P < .001). A reduction in intraoperative blood loss with preoperative embolization of mRCC to the spine before operative resection has been supported by other case reports and small case series that also demonstrated decreased operative time. [75] [76] [77] For patients who have mRCC involving the liver, transarterial embolization has been proposed as an alternative to partial hepatectomy for those with disease that Metastasis Treatment in Kidney Cancer/Psutka and Master progresses on immunotherapy and targeted therapy. 78 Yttrium-90 glass-microsphere radioembolization has been associated with a complete radiographic response in 16 of 17 patients. 79 In that series, the median OS from radioembolization was 22.8 months, and no grade 3 or 4 toxicities were reported. Further research is needed to quantify the comparative effectiveness and relative toxicity of embolization strategies like this compared with either partial hepatectomy or percutaneous thermal ablation strategies.
PROGNOSTIC FACTORS IN METASTASECTOMY: PATIENT SELECTION
When considering the incorporation of locally directed therapy into treatment for an individual patient with mRCC, it is imperative to be able to accurately estimate a patient's prognosis related to both the mRCC and the patient's competing comorbidities and to weigh the risks and benefits of locally directed therapies and their associated toxicity. To date, no level 1 evidence exists regarding the local treatment of metastatic disease, as noted above, and the potential for selection bias in the observational data that have been reviewed must be underscored. However, acknowledging these challenges, it is clear that locally directed therapy in the appropriately selected patient with mRCC may lead to benefits in terms of symptomatic palliation, potential durable local control, and PFS. Therefore, it is critically important to understand that selection criteria may be used to identify those patients who may derive benefit from locally directed therapy.
Prognostic Models and Risk Stratification
Various risk models have been developed to assist with risk stratification for patients with mRCC. One of the most widely relied upon models is the Memorial Sloan Kettering Cancer Center (MSKCC) risk grouping, which includes levels of lactate dehydrogenase, corrected calcium, and serum hemoglobin; Karnofsky performance status; and interval from nephrectomy. 80 This model initially was developed to identify patients who would benefit from cytoreductive nephrectomy. Eggener and colleagues used this schema to categorize 129 patients with mRCC into those with favorable-risk, intermediaterisk, or high-risk disease and observed that both favorablerisk disease and metastasectomy were independently associated with better survival. 73 Also commonly used is the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model, which was derived from a cohort of 645 patients with mRCC who received targeted therapy. 81 This risk model similarly incorporates hemoglobin below the lower limit of normal, calcium above the upper limit of normal, a Karnofsky performance score (KPS) 80%, and systemic disease within 1 year of RCC diagnosis, in addition to absolute neutrophil and platelet counts above the upper limit of normal. Although these risk scores may be used to generate an overall estimate of the expected survival for patients with mRCC, they have not been specifically validated in the metastasectomy literature and, as noted by Dabestani and colleagues in their systematic review, are reported infrequently in the available mRCC metastasectomy studies. 16 Among patients with mRCC who receive targeted therapy, concordance of risk prognostication between the MSKCC score and the IMDC model is approximately 0.66, likely indicative of the ongoing, continued need for additional refinements to prognostication methods. 82 In general, prognostic factors among metastasectomy are analyzed and discussed within relatively homogeneous cohorts with metastases affecting a specific organ or anatomic site. Overall, among patients who undergo metastasectomy, several indicators consistently are described as independently associated with survival outcomes, irrespective of mRCC location or modality of locally directed therapy. These include the ability to obtain a CM, 5,83-85 a solitary or low number of metastases 62, 83, 85, 86 and small size of metastases, 87 or an overall low burden of metastatic disease. 88 An additional factor associated with improved outcomes is an absence of local lymph node involvement in patients who have M1 RCC. 83, 89 Metastasis histology also has been associated independently with oncologic outcomes after metastasectomy, with pure clear cell histology associated with a decreased risk of mortality 87 ; however, these results should be interpreted with caution, because nonclear cell histology represents only a small portion of the cases included in available metastasectomy series and likely represents a biologically heterogeneous category, grouping together patients who have papillary RCC and aggressive RCC histologic variants, like those with sarcomatoid differentiation. 90 Conversely, any sarcomatoid component was independently associated with poor OS among patients with brain metastases who received local therapy. 91 
Metastasis Location
Many studies also have suggested that the location of RCC metastases is prognostic among patients with mRCC. Pulmonary metastases are most common, with an incidence ranging from 45% to 75% and a 5-year OS Review Article rate of 36% to 50%. Osseous metastases are the next most common, occurring in 15% to 34% of patients, with a 5-year OS rate of 35%. Hepatic metastases are observed in approximately 20% of patients, with a 5-year OS rate of 18% to 43%. 36, 92 In a series of 2027 patients with mRCC, the presence of hepatic metastases was associated independently with inferior oncologic outcomes compared with other metastatic sites. 93 Brain metastases similarly occur in approximately 17% of patients but are associated with a median survival of only 10.7 months and a 5-year OS rate of only 12%, and these data indicate that most patients will fare poorly, although a small subset of patients with brain metastases may experience prolonged survival. 94 For patients who have mRCC involving the central nervous system, treatment is often administered with palliative intent and may involve surgery, radiotherapy, SRS, and systemic therapies. Comparative studies have demonstrated equivalent 2-year OS and intracerebral control for SRS alone and SRS with whole-brain irradiation, both of which were superior to whole-brain irradiation alone. 95 A second study evaluated fractionated SRS plus metastasectomy with adjuvant radiotherapy versus conventional radiotherapy alone and demonstrated that survival did not differ significantly between the therapeutic arms, whereas 2-year local control was superior in the fractionated SRS group. 96 Such results led the European Association of Urology to recommend that, although surgical metastasectomy remains the most commonly used treatment option for noncentral nervous system lesions, alternative treatments like radiation should be considered equally appropriate for brain metastases; and they also highlighted the finding that radiotherapy to brain metastases may be of significant palliative benefit. 97 The use of surgical resection for mRCC brain metastases combined with adjuvant radiation therapy is becoming increasingly more common and potentially can produce greater local control.
Local recurrences within the retroperitoneum are comparatively much less common, occurring in 3% of patients, and have a 5-year OS ranging from 18% to 52%. In patients who had renal fossa recurrences alone, the median CSS was 0.7 years for those who underwent observation, 2.8 years for those who received systemic therapy alone, and 4.6 years for those who either underwent surgery or ablation or received radiation or some combination of local therapy. 32 Pancreatic metastases are most commonly metachronous, frequently occur as a solitary metastasis, 98, 99 and generally are considered more indolent, occurring in 1% of patients but with a 5-year OS rate of 72% to 88%. 98, 100 Similarly, thyroid metastases are relatively uncommon, occurring in 1% of patients, and are associated with a 5-year survival rate of 51%, leading many surgical oncologists to offer pancreatic and thyroid surgery to such patients. 5 Among patients who with thyroid metastases, a pattern of synchronous, isolated metastases to the pancreas was identified in 31% of those in a multiinstitutional cohort, leading to the recommendation that the discovery of RCC metastases in 1 location should prompt an evaluation of the other. 101 Jakubowski and colleagues reported on a series of 138 patients who underwent CM at a single organ site, including the adrenal, lung, liver, pancreas, or thyroid. 102 Postmetastasectomy, the 5-year recurrence-free and CSS rates were 27% and 84%, respectively. On univariate analysis, age, the number of metastases resected, and the time from nephrectomy to first recurrence were associated with recurrence-free survival; whereas maximum tumor size and sarcomatoid histology were associated with CSS. Furthermore, in that selected cohort, the 5-year recurrence-free survival rate for patients with metastases to the adrenal, liver, lung, pancreas, and thyroid was 32%, 27%, 22%, 43%, and not available, respectively, but was not statistically different (P 5 .14). However, as noted above, brain metastases are associated with an overall worse Figure 2 . This is an illustration of how cross-sectional imaging can be used to quantify lean-muscle cross-sectional surface area (red) in screening for sarcopenia or severe skeletal muscle wasting, which is an anatomic surrogate for frailty. The skeletal muscle index is calculated by normalizing the crosssectional surface area of lean muscle mass (in cm 2 ) by height (in m Cancer September 15, 2018 survival. Similarly, bone metastases are associated with an increased risk of local recurrence and CSM compared with other locations. In a series of 2000 patients with osseous metastases who received systemic therapy, osseous metastases were associated with inferior survival across risk categories. 93 
Performance Status and Frailty
Beyond tumor-specific factors, patient selection for metastasectomy also must address host-specific prognostic factors and their potential implications for both oncologic and peritreatment outcomes. Both the MSKCC and IMDC models incorporate the KPS into their composite risk assessment. Similarly, multiple observational metastasectomy series have demonstrated that the Eastern Cooperative Oncology Group performance status is independently associated with oncologic outcomes. 21, 73, 92, 94, 103 Preoperative performance status likewise demonstrated an association with postoperative performance status alone-whether or not the metastases were completely resectable-among patients who had pelvic bone metastases. 33 Furthermore, the KPS was identified as an important prognostic factor among 286 patients with RCC metastases to the brain who received radiotherapy. 104 It is noteworthy that, in the systematic review by Zaid et al assessing oncologic outcomes after CM versus incomplete/no metastasectomy, the independent association between decreased mortality and CM remained, even after adjustment for performance status. 17 Extrapolating from the data regarding perioperative outcomes and oncologic outcomes after cytoreductive nephrectomy in mRCC, other potential prognostic factors that may be important to consider in selecting a patient for definitive treatment of metastatic deposits include nutritional status as measured by pretreatment and posttreatment hypoalbuminemia levels, which have been associated independently with 6-month and 12-month CSM, respectively. 105 One area of research that has garnered substantial interest in recent years in the surgical oncology literature is the concept of frailty and how this relates to perioperative morbidity and mortality as well as oncologic outcomes. 106, 107 Frailty has been referred to as "functional age" compared with chronological age. Lean muscle mass wasting (which, in its most severe form, may be characterized as sarcopenia) is quantified using metrics of lean muscle mass, such as the skeletal muscle index, and is considered an anatomic surrogate for frailty. 108, 109 A quantitative factor that may be derived from measurements taken from routine cross-sectional imaging (Fig. 2) , sarcopenia has been identified as a highly prognostic factor in mRCC in terms of both prognosticating a patient's ability to tolerate systemic therapy 110 and assessing risk for mortality after nephrectomy for locally advanced RCC 111 and after cytoreductive nephrectomy. 112, 113 Future studies are needed to define how frailty (as measured by validated, patient-reported questionnaires) and sarcopenia as well as other patient-specific factors influence outcomes and thereby may inform patient selection for definitive treatment of metastases in mRCC. Table 1 summarizes the various tumor-specific and patient-specific prognostic factors that may be taken into consideration when evaluating a patient with mRCC for definitive treatment of the metastases. Figure 3 summarizes the different potential definitive treatments that may be used for metastases according to their location.
CONCLUSIONS AND FUTURE WORK
Definitive therapies directed against the metastatic deposits in mRCC represent an important component of the overall multidisciplinary treatment strategy for the patient with mRCC toward the dual objectives of extending both survival and the palliation of tumor-related symptoms. Although observational data supporting this practice are the most robust for surgical metastasectomy, there is support for the use of radiation, SRS, thermal ablation, and embolization of metastases. Indeed, CM is the only approach that is capable of rending a patient with mRCC free of disease and is associated with increases in survival and the time to systemic therapy.
For this reason, in the current guidelines put forth by the National Comprehensive Cancer Network, surgical metastasectomy and/or ablative techniques of metastases in nonsurgical candidates are advocated for patients who have stage IV RCC with a potentially resectable primary and/or oligometastatic disease. 15 The European Association of Urology RCC guidelines, which were developed on the basis of a systematic review of the available evidence, 16 acknowledge that the observational quality of the body of evidence supporting the practice of resecting the metastases preclude any general recommendations. 97 The guidelines panel specified that patients should be approached on a case-by-case basis and that, to achieve local control, risk profiles, performance status, patient preferences, and alternative techniques must be considered.
Given the dynamic landscape of mRCC management related to ever-changing options for systemic therapy, rapid developments in the field of targeted and novel immunotherapies, and recent advances in options for administering local treatment to metastatic deposits beyond surgical resection, recommendations regarding when and in which patient to optimally pursue definitive treatment of metastases remain a moving target. The results of ongoing clinical trials assessing the additive benefits of systemic therapies and various treatmentsequencing options are eagerly anticipated and will further inform the optimal incorporation of definitive treatment of metastases in the patient with mRCC.
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